{"id":"W2146701863","doi":"10.1016/s1470-2045(13)70501-1","title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":270,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Brentuximab vedotin; ABVD; Medicine; Dacarbazine; Internal medicine; Vinblastine; Oncology; Bleomycin; Phases of clinical research; Lymphoma; Surgery; Chemotherapy; CD30; Vincristine; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002848085,0.0003155717,0.0009736783,0.00006355608,0.0002277132,0.0001148325,0.0003395306,0.00009958682,0.0001187928],"category_scores_gemma":[0.00009739404,0.0001470138,0.00003470117,0.0002460288,0.0001261921,0.0002427176,0.0001187307,0.00008407543,0.0000673415],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004236396,"about_ca_system_score_gemma":0.0003970371,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005695325,"about_ca_topic_score_gemma":0.0006163563,"domain_scores_codex":[0.9981671,0.0002133949,0.000350334,0.0004670107,0.0002886041,0.0005135878],"domain_scores_gemma":[0.9978861,0.0007448471,0.0002903842,0.0006322617,0.0002929874,0.0001534334],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.08871958,0.1468432,0.5346357,0.0001037866,0.001647757,0.0003292241,0.002734086,0.00001027006,0.00005254526,0.0004097389,0.02769823,0.1968159],"study_design_scores_gemma":[0.3744762,0.0794137,0.5396059,0.00007753942,0.0006008687,0.00002559207,0.0003741914,0.0002078703,0.00004974413,0.0000622772,0.00490878,0.0001973617],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843252,0.00003838922,0.0000717009,0.004405242,0.0001612318,0.01005733,0.00004366791,0.00007878109,0.0008184957],"genre_scores_gemma":[0.9900072,0.00002492013,0.002380936,0.001796026,0.0002114405,0.004879539,0.0002065178,0.00004976949,0.0004436318],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2857566,"threshold_uncertainty_score":0.5995047,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05715420935216558,"score_gpt":0.3593148764130715,"score_spread":0.3021606670609059,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}